½ÃÀ庸°í¼­
»óǰÄÚµå
1671179

¼¼°èÀÇ ³ëÀοë ÀǾàǰ ½ÃÀå, ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Ä¡·áÁ¦º°, »óź°, À¯Åë ä³Îº°, Áö¿ªº° - ¿¹Ãø(2025-2034³â)

Global Geriatric Medicines Market Size, Share, Trends, Industry Analysis Report: By Therapeutics, Condition, Distribution Channel, and Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 117 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°è ³ëÀοë ÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 3,405¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼³¹®Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

³ëÀοë ÀǾàǰÀº ³ëÀÎ ¾à¹° Ä¡·á·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç ³ëÀÎÀ» À§ÇØ Æ¯º°È÷ °í¾ÈµÈ ÀǾàǰ Ä¡·áÀÇ °³¹ß, »ç¿ë ¹× °ü¸®¿¡ ÁßÁ¡À» µÐ ÀÇÇÐ Àü¹® ºÐ¾ß¸¦ ¸»ÇÕ´Ï´Ù. ÀÌ ºÐ¾ß´Â ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, °üÀý¿°, ½Å°æ Áúȯ, È£Èí±â Áúȯ µîÀÇ ¸¸¼º ÁúȯÀ» Æ÷ÇÔÇÑ ³ëÈ­¿Í °ü·ÃµÈ µ¶Æ¯ÇÑ »ý¸®Àû º¯È­¿Í °Ç°­ ¹®Á¦¸¦ ÇØ°áÇÕ´Ï´Ù.

³ëÀοë ÀǾàǰ ½ÃÀåÀº ¼¼°è °í·ÉÈ­ Àα¸ Áõ°¡¿Í ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, °üÀý¿°, ½Å°æ ÅðÇ༺ Áúȯ°ú °°Àº ¸¸¼º Áúȯ ¹× ³ëÈ­ °ü·Ã Áúº´ÀÇ À¯º´·üÀÇ »ó½Â¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ºñÁî´Ï½º ±âȸ·Î´Â ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀü, ³ªÀÌ¿¡ ƯȭµÈ ¾à¹° Á¦Á¦ °³¹ß, ½ÅÈï±¹ ½ÃÀåÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó È®´ë µîÀÌ ÀÖ½À´Ï´Ù.

¿ø°Ý ÀÇ·á ¹× ¿þ¾î·¯ºí ´Ü¸»±â¿Í °°Àº µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕ°ú °°Àº µ¿ÇâÀº ³ëÀÎ Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Çâ»ó½Ã۰í Ä¡·áÀÇ ¾îµå·¹½ÌÀ» °³¼±ÇÕ´Ï´Ù. ¶ÇÇÑ ¿¹¹æ ÀÇ·á ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ÅõÀÚµµ Áõ°¡Çϰí ÀÖÀ¸¸ç ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ³ëÀÎ ÀǾàǰ ½ÃÀåÀº Çõ½ÅÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

³ëÀοë ÀǾàǰ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

°í·ÉÀÚÀÇ ´ç´¢º´ À¯º´·üÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ç×´ç´¢º´¾à ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ µî Çõ½ÅÀû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù.

°í·ÉÀÚÀÇ ½ÉÀå °ü·Ã ÁúȯÀÇ ºÎ´ãÀÌ Å©¹Ç·Î, ¼øÈ¯±â°è ÁúȯÀÌ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ´Â ÇÑÆí, ¾ËÃ÷ÇÏÀ̸Ӻ´À̳ª ÆÄŲ½¼º´ÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ½Å°æ°è ÁúȯÀÌ °¡Àå ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ÇÑÆí, ¿Â¶óÀÎ ¾à±¹Àº ÀçÅà ¹è¼ÛÀÇ ÆíÀǼº°ú µðÁöÅÐ Çコ Ç÷§ÆûÀÇ Ã¤¿ë Áõ°¡¿¡ µû¶ó ±Þ¼ºÀåÀ» ±â·ÏÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â Áøº¸µÈ °Ç°­ °ü¸® ÀÎÇÁ¶ó¿Í ³ëÀÎ Àα¸ Áõ°¡¿¡ ÀÇÇØ Áö¿øµÇ°í ½ÃÀåÀ» µ¶Á¡ÇÕ´Ï´Ù. ¹Ý¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³ëÀÎ Àα¸ È®´ë¿Í ÀÇ·á Á¢±Ù °³¼±¿¡ ÈûÀÔ¾î °¡Àå ±Þ¼ºÀåÇÏ´Â Áö¿ªÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°è ³ëÀοë ÀǾàǰ ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ÇöȲ
  • ³ëÀοë ÀǾàǰ ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
      • ¿¬·É¿¡ µû¸¥ ÀǾàǰ ¼ö¿ä Áõ°¡
      • °í·É ȯÀÚ¿ë ¸ÂÃãÇü ÀÇ·áÀÇ Áøº¸
    • ¾ïÁ¦¿äÀΰú °úÁ¦
      • °í·ÉÀÚ ÇコÄɾîÀÇ °í¾×ÀÇ ºñ¿ë
  • PESTEL ºÐ¼®
  • ³ëÀοë ÀǾàǰ ½ÃÀåÀÇ ÀÀ¿ë µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ³ëÀοë ÀǾàǰ ½ÃÀå : Ä¡·áÁ¦º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • ÁøÅëÁ¦
  • ½ºÅ¸Æ¾
  • Ç×´ç´¢º´¾à
  • ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦(PPI)
  • Ç×ÀÀ°íÁ¦
  • Ç×Á¤½Åº´¾à
  • ±âŸ

Á¦6Àå ¼¼°è ³ëÀοë ÀǾàǰ ½ÃÀå : »óź°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • ½ÉÇ÷°ü Áúȯ
  • ½Å°æÁúȯ
  • ¾Ï
  • ´ç´¢º´°ú ´ë»ç Àå¾Ö
  • È£Èí±â Áúȯ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ³ëÀοë ÀǾàǰ ½ÃÀå : À¯Åë ä³Îº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ ³ëÀοë ÀǾàǰ ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ³ë³â¿ë ÀǾàǰ ½ÃÀåÀÇ Æò°¡, Áö¿ª, 2020³â-2034³â
  • ºÏ¹Ì
    • ºÏ¹Ì : Ä¡·áÁ¦º°, 2020³â-2034³â
    • ºÏ¹Ì : »óź°, 2020³â-2034³â
    • ºÏ¹Ì : À¯Åë ä³Îº°, 2020³â-2034³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : Ä¡·áÁ¦º°, 2020³â-2034³â
    • À¯·´ : »óź°, 2020³â-2034³â
    • À¯·´ : À¯Åë ä³Îº°, 2020³â-2034³â
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç: Ä¡·áÁ¦º°, 2020³â-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç: »óź°, 2020³â-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç: À¯Åë ä³Îº°, 2020³â-2034³â
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«: Ä¡·áÁ¦º°, 2020³â-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : »óź°, 2020³â-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : À¯Åë ä³Îº°, 2020³â-2034³â
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : Ä¡·áÁ¦º°, 2020³â-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : »óź°, 2020³â-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : À¯Åë ä³Îº°, 2020³â-2034³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • È®´ë ¹× Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ, Çù¾÷, ÇÕÀÇ, °ø°³

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Pfizer Inc.
  • Novartis International AG
  • Sanofi
  • GlaxoSmithKline
  • Merck & Co.
  • AbbVie
  • AstraZeneca
  • Johnson & Johnson
  • Eli Lilly and Company
  • Roche
SHW 25.03.18

The global geriatric medicines market size is expected to reach USD 340.50 billion by 2034, according to a new study by Polaris Market Research. The report "Geriatric Medicines Market Size, Share, Trends, Industry Analysis Report: By Therapeutics (Analgesics, Statins, Antidiabetic, Proton Pump Inhibitors (PPIs), Anticoagulant, Antipsychotic, and Others), Condition, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Geriatric medicines, also known as geriatric pharmacotherapy, refer to a specialized branch of medicine focused on the development, use, and management of pharmaceutical treatments designed specifically for elderly individuals. This area addresses the unique physiological changes and health challenges associated with aging, including chronic conditions such as cardiovascular diseases, diabetes, arthritis, neurological disorders, and respiratory diseases.

The geriatric medicines market is driven by the growing global aging population and the rising prevalence of chronic and age-related diseases such as cardiovascular conditions, diabetes, arthritis, and neurodegenerative disorders. Key opportunities in the market include advancements in personalized medicine, the development of age-specific drug formulations, and the expansion of healthcare infrastructure in emerging markets.

Trends such as the integration of digital health technologies, including telemedicine and wearable devices, are enhancing access to care and improving treatment adherence among older adults. The market is also seeing increasing investments in preventive healthcare and biosimilars to provide cost-effective solutions. Overall, the geriatric medicines market is poised for steady growth as demand for innovative and accessible treatments continues to rise globally.

Geriatric Medicines Market Report Highlights

The antidiabetic segment dominates the market due to the high prevalence of diabetes among the elderly, with rising demand for innovative treatments such as GLP-1 receptor agonists driving growth.

Cardiovascular diseases account for the largest geriatric medicines market share, driven by the significant burden of heart-related conditions in older adults, while neurological disorders are the fastest-growing segment due to the increasing prevalence of Alzheimer's and Parkinson's diseases.

Hospital pharmacies lead the market as they are primary points of care for elderly patients with chronic diseases, whereas online pharmacies are registering the fastest growth due to the convenience of home delivery and the rising adoption of digital health platforms.

North America dominates the market, supported by advanced healthcare infrastructure and a growing elderly population, while Asia Pacific is the fastest-growing region, fueled by its expanding geriatric demographic and improving healthcare access.

Polaris Market Research has segmented the geriatric medicines market report based on therapeutics, condition, distribution channel, and region:

By Therapeutics Outlook (Revenue-USD Billion, 2020 - 2034)

  • Analgesics
  • Statins
  • Antidiabetic
  • Proton Pump Inhibitors (PPIs)
  • Anticoagulant
  • Antipsychotic
  • Others

By Condition Outlook (Revenue-USD Billion, 2020 - 2034)

  • Cardiovascular Diseases
  • Neurological Disorders
  • Cancer
  • Diabetes & Metabolic Disorders
  • Respiratory Diseases
  • Others

By Distribution Channel Outlook (Revenue-USD Billion, 2020 - 2034)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Geriatric Medicines Market Insights

  • 4.1. Geriatric Medicines Market - Market Snapshot
  • 4.2. Geriatric Medicines Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing Demand for Age-Specific Medications
      • 4.2.1.2. Advancements in Personalized Medicine for Elderly Patients
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Geriatric Healthcare
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Geriatric Medicines Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Geriatric Medicines Market, by Therapeutics

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
  • 5.3. Analgesics
    • 5.3.1. Global Geriatric Medicines Market, by Analgesics, by Region, 2020-2034 (USD Billion)
  • 5.4. Statins
    • 5.4.1. Global Geriatric Medicines Market, by Statins, by Region, 2020-2034 (USD Billion)
  • 5.5. Antidiabetic
    • 5.5.1. Global Geriatric Medicines Market, by Antidiabetic, by Region, 2020-2034 (USD Billion)
  • 5.6. Proton Pump Inhibitors (PPIs)
    • 5.6.1. Global Geriatric Medicines Market, by Proton Pump Inhibitors (PPIs), by Region, 2020-2034 (USD Billion)
  • 5.7. Anticoagulant
    • 5.7.1. Global Geriatric Medicines Market, by Anticoagulant, by Region, 2020-2034 (USD Billion)
  • 5.8. Antipsychotic
    • 5.8.1. Global Geriatric Medicines Market, by Antipsychotic, by Region, 2020-2034 (USD Billion)
  • 5.9. Others
    • 5.9.1. Global Geriatric Medicines Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Geriatric Medicines Market, by Condition

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
  • 6.3. Cardiovascular Diseases
    • 6.3.1. Global Geriatric Medicines Market, by Cardiovascular Diseases, by Region, 2020-2034 (USD Billion)
  • 6.4. Neurological Disorders
    • 6.4.1. Global Geriatric Medicines Market, by Neurological Disorders, by Region, 2020-2034 (USD Billion)
  • 6.5. Cancer
    • 6.5.1. Global Geriatric Medicines Market, by Cancer, by Region, 2020-2034 (USD Billion)
  • 6.6. Diabetes & Metabolic Disorders
    • 6.6.1. Global Geriatric Medicines Market, by Diabetes & Metabolic Disorders, by Region, 2020-2034 (USD Billion)
  • 6.7. Respiratory Diseases
    • 6.7.1. Global Geriatric Medicines Market, by Respiratory Diseases, by Region, 2020-2034 (USD Billion)
  • 6.8. Others
    • 6.8.1. Global Geriatric Medicines Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Geriatric Medicines Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Global Geriatric Medicines Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Billion)
  • 7.4. Retail Pharmacy
    • 7.4.1. Global Geriatric Medicines Market, by Retail Pharmacy, by Region, 2020-2034 (USD Billion)
  • 7.5. Online Pharmacy
    • 7.5.1. Global Geriatric Medicines Market, by Online Pharmacy, by Region, 2020-2034 (USD Billion)

8. Global Geriatric Medicines Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Geriatric Medicines Market Assessment, b y Geography, 2020-2034 (USD Billion)
  • 8.3. Geriatric Medicines Market - North America
    • 8.3.1. North America: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
    • 8.3.2. North America: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
    • 8.3.3. North America: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Geriatric Medicines Market - US
      • 8.3.4.1. US : Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.3.4.2. US : Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.3.4.3. U S: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Geriatric Medicines Market - Canada
      • 8.3.5.1. Canada: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Geriatric Medicines Market - Europe
    • 8.4.1. Europe: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Geriatric Medicines Market - UK
      • 8.4.4.1. UK: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Geriatric Medicines Market - France
      • 8.4.5.1. France: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Geriatric Medicines Market - Germany
      • 8.4.6.1. Germany: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Geriatric Medicines Market - Italy
      • 8.4.7.1. Italy: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Geriatric Medicines Market - Spain
      • 8.4.8.1. Spain: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Geriatric Medicines Market - Netherlands
      • 8.4.9.1. Netherlands: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Geriatric Medicines Market - Russia
      • 8.4.10.1. Russia: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Geriatric Medicines Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Geriatric Medicines Market - Asia Pacific
    • 8.5.1. Asia Pacific: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Geriatric Medicines Market - China
      • 8.5.4.1. China: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Geriatric Medicines Market - India
      • 8.5.5.1. India: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Geriatric Medicines Market - Malaysia
      • 8.5.6.1. Malaysia: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Geriatric Medicines Market - Japan
      • 8.5.7.1. Japan: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Geriatric Medicines Market - Indonesia
      • 8.5.8.1. Indonesia: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Geriatric Medicines Market - South Korea
      • 8.5.9.1. South Korea: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Geriatric Medicines Market - Australia
      • 8.5.10.1. Australia: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Geriatric Medicines Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Geriatric Medicines Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Geriatric Medicines Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Geriatric Medicines Market - UAE
      • 8.6.5.1. UAE: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Geriatric Medicines Market - Israel
      • 8.6.6.1. Israel: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Geriatric Medicines Market - South Africa
      • 8.6.7.1. South Africa: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Geriatric Medicines Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Geriatric Medicines Market - Latin America
    • 8.7.1. Latin America: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Geriatric Medicines Market - Mexico
      • 8.7.4.1. Mexico: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Geriatric Medicines Market - Brazil
      • 8.7.5.1. Brazil: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Geriatric Medicines Market - Argentina
      • 8.7.6.1. Argentina: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Geriatric Medicines Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Geriatric Medicines Market, by Therapeutics, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Geriatric Medicines Market, by Condition, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Geriatric Medicines Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Pfizer Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Novartis International AG
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Sanofi
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. GlaxoSmithKline
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Merck & Co.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. AbbVie
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. AstraZeneca
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Johnson & Johnson
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Eli Lilly and Company
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Roche
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦